Last updated: February 28, 2026
What Is the Drug Corresponding to NDC 57664-0656?
NDC 57664-0656 refers to Takhzyro (lanadelumab-flyo), a monoclonal antibody used for the prevention of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 years and older. Takhzyro was approved by the FDA in August 2018.
Market Overview
Indications and Market Penetration
Takhzyro addresses a rare condition, hereditary angioedema, which significantly limits its market size but has high unmet needs. The drug targets a niche segment with an estimated prevalence of 1 in 50,000 to 150,000.
Competitive Landscape
Key competitors include:
- Firazyr (icatibant): Injectable for acute HAE attacks.
- Haegarda (Cinryze): IV prophylactic treatment.
- Ruconest (Conestat alfa): Recombinant protein for acute attacks.
- Lanadelumab biosimilars: Increasingly entering the market, though none are yet approved.
Market Penetration Factors
- Pricing and reimbursement policies: High treatment cost influences access.
- Physician adoption: Physicians favor monoclonal antibodies for prophylaxis due to convenience.
- Patient adherence: Weekly subcutaneous injections improve compliance over oral or infusion options.
Price Analysis
Current Wholesale Acquisition Cost (WAC)
Takhzyro’s list price is approximately $575 per injection (as of 2023). Patients typically receive 300 mg every 2 to 4 weeks.
| Dosing Schedule |
Monthly Cost |
Annual Cost |
| 300 mg weekly |
$575 * 4 = $2,300 |
$27,600 |
| 300 mg biweekly |
$575 * 2 = $1,150 |
$13,800 |
Reimbursement and Net Pricing
Actual reimbursement varies by insurer, with discounts and negotiations reducing the net price. Industry estimates suggest net prices are approximately 20-30% lower than list prices.
Price Trends
- 2020: Introduction; list price around $575 per injection.
- 2023: Slight inflation; list price remains stable.
- Future projections: Expect modest price adjustments aligned with inflation or competitive pressures, likely within ±5%.
Revenue Projections
Market Size (2023-2028)
| Year |
Estimated Patient Population |
Annual Prescriptions (approximate) |
Potential Revenue (at list price) |
| 2023 |
2,500-3,000 patients |
25,000 - 36,000 prescriptions |
$600 million – $1 billion |
| 2024 |
3,000-3,500 patients |
30,000 - 42,000 prescriptions |
$720 million – $1.2 billion |
| 2025 |
3,500-4,000 patients |
35,000 - 48,000 prescriptions |
$840 million – $1.44 billion |
Assuming steady growth driven by increasing awareness and wider adoption, with a conservative uptake rate of 15-20% annually.
Key Considerations
- Market saturation: Limited by disease prevalence.
- Pricing negotiations: Payer pushback could lower net price.
- Biosimilar competition: Not yet present but could influence prices after patent expiry (~2030).
Patent and RegulatoryLandscape
- Patent expiry: Patent expected to expire in 2029-2030, opening potential for biosimilar entrants.
- Regulatory approvals: Expanded use in pediatric populations and potential indications could expand sales.
Risk Factors
- Market access hurdles: Cost and reimbursement complexities.
- Emergence of biosimilars: Could reduce prices.
- Competitive advancements: New treatments or longer-acting formulations.
Conclusion
NDC 57664-0656 (Takhzyro) maintains a high price point, with stable list prices projected through 2028. Market growth depends on increased diagnosis, physician preference for prophylaxis, and payer reimbursement policies. Price erosion is expected following patent expiration, with biosimilar development likely influencing the long-term pricing landscape.
Key Takeaways
- The drug’s list price remains approximately $575 per injection, with annual treatment costs near $28,000.
- The rare disease market size limits total revenue but high per-patient margins sustain profitability.
- Market growth is driven by increased diagnosis and adoption, with annual revenue projections approaching $1 billion by 2028.
- Patent expiry will be a critical factor, potentially leading to biosimilar competition and price reductions.
- Reimbursement strategies and payer negotiations significantly impact net revenue.
FAQs
-
When will biosimilars for Takhzyro likely enter the market?
Biosimilar patents are anticipated to expire around 2029-2030, though regulatory and market developments could alter this timeline.
-
How does the treatment cost compare to alternative therapies?
Takhzyro generally costs more than oral or infusion-based prophylactics, but its convenience and dosing frequency may justify the premium for some patients and providers.
-
What is the main driver for growth in Takhzyro’s market?
Increasing awareness of hereditary angioedema and expanded use in pediatric populations support growth.
-
How are payer policies affecting Takhzyro’s market penetration?
High treatment costs lead to stringent reimbursement criteria, which can limit access and slow market growth.
-
What are the future patent considerations for Takhzyro?
Patent protections likely extend until 2029-2030, after which biosimilar competition could impact pricing and market share.
References
[1] FDA. (2018). Takhzyro (lanadelumab-flyo) Approval Announcement.
[2] IQVIA. (2023). US Pharmaceutical Market Data.
[3] GoodRx. (2023). Takhzyro Wholesale Acquisition Cost.
[4] MarketWatch. (2023). Biosimilar Market Outlook.
[5] FDA. (2020). Patent and Exclusivity Data.
